|
|
在研机构- |
|
|
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期- |
A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study
This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of BOW015 (infliximab-EPIRUS) compared to Remicade in subjects with active Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy.
100 项与 Epirus Biopharmaceuticals (Switzerland) GmbH 相关的临床结果
0 项与 Epirus Biopharmaceuticals (Switzerland) GmbH 相关的专利(医药)
100 项与 Epirus Biopharmaceuticals (Switzerland) GmbH 相关的药物交易
100 项与 Epirus Biopharmaceuticals (Switzerland) GmbH 相关的转化医学